Urodynamix and Timm Medical Sign Development and Distribution Agreement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 6, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE: URO.V) announced today that it has entered into a product development and distribution agreement with Timm Medical Technologies Inc., a subsidiary of Plethora Solutions Holdings PLC (AIM: PLC). Timm Medical is a leading manufacturer and distributor of men's health and erectile dysfunction (ED) products.

In exchange for minimum quantities and additional royalty payments of up to $100,000, the agreement grants Timm Medical exclusive worldwide distribution rights for the ED application of the near infrared spectroscopy (NIRS) technology developed by Urodynamix for the measurement of penile blood flow in male ED patients. Urodynamix and Timm Medical will collaborate on the product design and regulatory approvals in the United States and worldwide, and Urodynamix will retain all ownership of NIRS ED intellectual property.

Subject to regulatory approvals, Timm Medical expects to begin marketing NIRS ED products in the United States in 2009 via its approximately 35 member field sales force calling on specialist urology clinics. These efforts will be supplemented by an in-house support team interacting directly with patients. NIRS ED products will also be marketed internationally via an extensive distributor network upon regulatory approval.

Urodynamix's NIRS ED technology provides an objective, user-friendly and non-invasive technique to replace existing technologies for evaluating penile hemodynamics in male patients with ED and those undergoing penile rehabilitation following prostatic surgery. Existing imaging modalities for penile blood flow are highly operator dependent and are typically performed and interpreted by an experienced radiologist.

"Urodynamix is very pleased to partner with Timm Medical, the leading manufacturer and distributor of men's health and ED products in the United States," commented Barry Allen, President and CEO of Urodynamix. "This agreement is another example of the successful implementation of our strategy to partner our proprietary NIRS applications with equipment providers who share our vision. Timm Medical has a reputation for quality and is well known for successfully introducing medical devices to their markets."

The American Urological Association's Erectile Dysfunction Clinical Guidelines Panel has noted that "new, clinically applicable instruments are needed to diagnose ED and to assess treatment satisfaction." Other methods of vascular evaluation, such as cavernosometry or penile ultrasonography, remain controversial due to a lack of standardized diagnostic methods.

About Timm Medical Technologies

Timm Medical is a leading manufacturer and distributor of men's health products, including Rigiscan(R) and the ErecAid(R) vacuum therapy system, a reimbursed, easy to use, on demand treatment for ED that recently received a unique product label extension for recovery following prostatic surgery. Timm Medical's U.S.-based sales infrastructure is comprised of a field force calling on urology clinics and an international distributor network.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contacts

Craig Pamplin
Urodynamix Technologies Ltd.
Director, Corporate Development and Communications
(604) 638-0247
Email: cpamplin@urodynamix.com
Website: www.urodynamix.com